Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Waldencast plc
Report date July 30, 2026 · Filed August 07, 2026
Section 16 reporting ended · disclosed 2026-08-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-30 · Disposition to issuer · Disposed 264,294 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election. F2: Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical. F3: On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
F2: Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
F3: On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2026 Filed Aug 7, 2026 20:10 UTC | Waldencast plc WALD · Entity 6419 | Disposition to issuerRestricted Stock Units · Derivative | 264,294 | $2.00 | $528,588.00 |
DisclosureSEC source: 0001840199-26-000093 · wk-form4_1786133456.xml · derivative · entry 1 Brousset Michel · CIK 0001841075 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 264,294 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election. F2 · kind: Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical. F3 · derivative.exercise_date: On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027. F3 · derivative.expiration_date: On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.